e15720 Background: This study was conducted to evaluate the efficacy as well as toxicity of oral S-1 with concurrent hypofractionated simultaneous integrated boost radiotherapy for metastatic pancreatic cancer using helical Tomotherapy. Methods: Patients with metastatic pancreatic cancer, adequate organ and marrow function and no prior anticancer therapy were enrolled in our study. S-1 was administered orally at a day of 40mg/m2 twice daily from day for 2 weeks, repeated every 3 weeks. Dose to the primary lesion was delivered as PTV for 50Gy, CTV for 60Gy and GTV for 70Gy in 15 to 20 fractions. Radiation induced toxicities were evaluated with the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.02. The overall survival (OS), progressive-free survival (PFS) and freedom from local progression (FFLP) were estimated using the Kaplan-Meier survival curve. Results: 45 patients were enrolled in this prospective clinical study. Pain relief rate was 91.7% (33/36). 1 year FFLP rate of the pancreatic lesion was 92.5%. 1 year OS rate was 17.6%. 1 year PFS was 4.2%. Median OS was 6 months. Grade 3 gastrointestinal reaction and blood reaction both appeared in 3 cases (13.3%). Conclusions: S-1 with concurrent hypofractionated simultaneous integrated boost radiotherapy using helical Tomotherapy resulted in high pain relief rate for patient with metastatic pancreatic cancer, with a tolerable side effect.
Elective nodal irradiation with simultaneous integrated boost stereotactic body radiotherapy for pancreatic cancer: Analyses of planning feasibility and geometrically driven DVH prediction model
